Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel

Exclusion Criteria

• •Have any medical conditions that precludes administration of Benepali according to Summary of Product Characteristics (SmPC), such as the following:
• •Hypersensitivity to the Benepali active substance, or to any of the associated excipients
• •Sepsis, or risk of sepsis
• •Active clinically significant local or chronic viral, bacterial or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 2 months prior to enrollment
• •Show any clinical sign or medical condition not allowing for treatment continuation (of etanercept) in the judgment of the Investigator
• •Treatment with another biologic agent
• •Are currently receiving or have previously received any therapies that would preclude administration of Benepali, such as the following:
• •Immunizations with live or live-attenuated vaccines within the last 6 months prior to transition point and throughout the observation period
• •Treatment with investigational agents within the last 6 months prior to transition point and during the period of observation.
• •Any other unspecified reasons that would, in the opinion of the Investigator, make the patient unsuitable for enrollment.